The estimated Net Worth of Peter Tai Ching Ho is at least $3.1 Tausend dollars as of 24 October 2017. Peter Ho owns over 15,000 units of Aravive Inc stock worth over $925 and over the last 10 years Peter sold ARAV stock worth over $2,178.
Sign up
Peter Ho ARAV stock SEC Form 4 insiders trading
Peter has made over 15 trades of the Aravive Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Peter exercised 15,000 units of ARAV stock worth $134,700 on 24 October 2017.
The largest trade Peter's ever made was exercising 15,000 units of Aravive Inc stock on 24 October 2017 worth over $134,700. On average, Peter trades about 3,738 units every 41 days since 2014. As of 24 October 2017 Peter still owns at least 23,123 units of Aravive Inc stock.
You can see the complete history of Peter Ho stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Peter Ho's mailing address?
Peter's mailing address filed with the SEC is C/O ARAVIVE, INC., RIVER OAKS TOWER,, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON, TX, 77098.
Insiders trading at Aravive Inc
Over the last 6 years, insiders at Aravive Inc have traded over $107,045 worth of Aravive Inc stock and bought 151,333 units worth $1,102,898 . The most active insiders traders include Srinivas Akkaraju, Fredric N Eshelman Ventures... und Shahzad Malik. On average, Aravive Inc executives and independent directors trade stock every 75 days with the average trade being worth of $11,962. The most recent stock trade was executed by Fredric N Eshelman Ventures... on 1 April 2022, trading 4,545,455 units of ARAV stock currently worth $181,818.
What does Aravive Inc do?
versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.
What does Aravive Inc's logo look like?
Complete history of Peter Ho stock trades at Epizyme Inc und Aravive Inc
Aravive Inc executives and stock owners
Aravive Inc executives and other stock owners filed with the SEC include:
-
Gail McIntyre,
President, Chief Executive Officer, Director -
Vinay Shah,
Chief Financial Officer -
Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D.,
Pres, CEO & Director -
Dr. Reshma Rangwala M.D., Ph.D.,
Chief Medical Officer -
Amato Giaccia,
Independent Director -
Raymond Tabibiazar,
Independent Director -
Eric Zhang,
Independent Director -
Dr. Fredric N. Eshelman Pharm.D.,
Exec. Chairman -
Mike Zanoni,
IR Contact Officer -
Michael Rogers,
Director -
Reshma Rangwala,
Chief Medical Officer -
Fredric Eshelman,
Independent Chairman of the Board -
Kenneth L. Guernsey,
Sec. -
Dr. Randy L. Anderson,
Sr. VP of Data Sciences -
Joseph T. Schepers,
VP of Investor Relations -
Dr. Joshua Silverman Ph.D.,
Co-Founder -
Dr. Jeffrey L. Cleland,
Co-Founder -
Maria Carolina Petrini,
Chief Commercial Officer -
Robert B. Geller,
Chief Medical Officer -
Leonard Scott Dove,
Chief Operating Officer -
Rekha Hemrajani,
-
Srinivas Akkaraju,
Director -
Jay Shepard,
President and CEO -
Kevin Haas,
VP, Finance and PAO -
Shahzad Malik,
Director -
Robert Hoffman,
Director -
Peter Tai Ching Ho,
Director -
John Hohneker,
Director -
Sigurd Kirk,
Director -
Rudy Howard,
Chief Financial Officer